An Open-Label, Randomized, Single-Dose, 2-Period Crossover Study to Determine the Effect of a High-Fat Meal on the Relative Bioavailability and Pharmacokinetics of a Single Dose of the 240 mg Formulation of Neratinib in Healthy Subjects.

Trial Profile

An Open-Label, Randomized, Single-Dose, 2-Period Crossover Study to Determine the Effect of a High-Fat Meal on the Relative Bioavailability and Pharmacokinetics of a Single Dose of the 240 mg Formulation of Neratinib in Healthy Subjects.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 11 May 2012

At a glance

  • Drugs Neratinib (Primary)
  • Indications Breast cancer; Non-small cell lung cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Pfizer; Puma Biotechnology; Wyeth
  • Most Recent Events

    • 11 May 2012 Company [Puma Biotechnology] added as trial association as reported by ClinicalTrials.gov.
    • 01 Aug 2011 Actual initiation date (Aug 2012) added as reported by ClinicalTrials.gov.
    • 29 Jul 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top